Article

Hypoxia upregulates ovarian cancer invasiveness via the binding of HIF-1α to a hypoxia-induced, methylation free hypoxia response element (HRE) of S100A4 gene.

International Journal of Cancer (Impact Factor: 5.01). 01/2012;
0 Followers
 · 
91 Views
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: The dependence of final vibrational action and collision time on the initial vibrational phase of H2 is examined on a model potential-energy surface (PES) for H2-W(001) collisions and it is shown that the switching region between the reactive and nonreactive bands is a fractal zone regardless of the details of the PES provided the dissociation probability is non-zero and less than unity.
    Surface Science 11/1990; 237(1-3):266-272. DOI:10.1016/0039-6028(90)90538-J · 1.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hypoxia-inducible factors (HIFs) are master regulators of angiogenesis and cellular adaptation in hypoxic microenvironments. Accumulating evidence indicates that HIFs also regulate cell survival, glucose metabolism, microenvironmental remodeling, cancer metastasis, and tumor progression, and thus, HIFs are viewed as therapeutic targets in many diseases. Epigenetic changes are involved in the switching 'on' and 'off' of many genes, and it has been suggested that the DNA hypermethylation of specific gene promoters, histone modifications (acetylation, phosphorylation, and methylation) and small interfering or micro RNAs be regarded epigenetic gene targets for the regulation of disease-associated cellular changes. Furthermore, the hypoxic microenvironment is one of the most important cellular stress stimuli in terms of the regulation of cellular epigenetic status via histone modification. Therefore, drug development and therapeutic approaches to ischemic diseases or cancer for targeting HIFs by modulation of epigenetic status become an attractive area. Here, the authors provide a review of the literature regarding the targeting of HIF, a key modulator of hypoxic-cell response under various disease conditions, by modulating histone or DNA using endogenous small RNAs or exogenous chemicals.
    Archives of Pharmacal Research 02/2013; DOI:10.1007/s12272-013-0058-x · 1.75 Impact Factor